BZO is the abbreviation for benzodiazepines on a drug screening panel. When a test comes back positive for BZO, it means the immunoassay detected metabolites consistent with benzodiazepine use, but that initial result is more of a flag than a final verdict. The screening technology has well-documented blind spots and false-positive triggers, so what a BZO result actually tells you depends heavily on what happens next.
What Benzodiazepines Are and Why They Show Up on Drug Panels
Benzodiazepines are a class of prescription sedatives that work by enhancing the activity of a neurotransmitter called GABA in the brain, which dampens nervous system activity and produces calming, sleep-promoting, and muscle-relaxing effects.1PubMed Central. Benzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective Common prescribed benzodiazepines include diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), and temazepam (Restoril). They are classified as Schedule IV controlled substances in the United States and carry FDA black box warnings due to risks of dependence and dangerous interactions with other sedating drugs.2PubMed Central. Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse
Because benzodiazepines carry abuse potential and interact dangerously with opioids and alcohol, drug testing panels routinely screen for them. The BZO line on a standard urine drug screen is designed to flag the presence of benzodiazepine metabolites. You will see it on workplace panels, pain management monitoring, emergency department toxicology screens, and substance abuse treatment programs.
How the BZO Screening Test Actually Works
The initial BZO test on a standard drug panel is an immunoassay. It uses antibodies designed to react with a specific benzodiazepine metabolite, most commonly oxazepam, which serves as a shared breakdown product for many different benzodiazepines. The test is typically calibrated with oxazepam at a cutoff concentration of 200 ng/mL, meaning the sample has to contain at least that much of the target metabolite (or something the antibodies cross-react with) to register as positive.3PubMed Central. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens
This is important because the test is not identifying a specific drug. It is looking for a family resemblance. The antibodies in the immunoassay recognize a general chemical structure, and anything that looks similar enough to that structure can trigger a positive. That design choice was intentional: the original drug screening framework was built for workplace testing under federal guidelines, where the priority was catching true positives with a low false-positive rate rather than identifying every possible substance.4The Journal of Applied Laboratory Medicine. Is This Drug Screen Really Negative? Special Investigation of Drug Screening in Pediatrics The tradeoff is that some benzodiazepines slip through undetected, while some non-benzodiazepine substances get flagged.
Why a Positive BZO Does Not Always Mean Benzodiazepine Use
False positives on BZO screens happen, and they are documented in the medical literature. The NSAID oxaprozin (brand name Daypro), prescribed for arthritis, has been reported to cause false-positive benzodiazepine results on urine drug panels.5JAMA. False-positive Benzodiazepine Urine Test Due to Oxaprozin The antidepressant sertraline (Zoloft) has also been associated with false-positive BZO screening results. A chart analysis found that among unexplained positive benzodiazepine screens, a notable proportion of patients were taking sertraline, suggesting it may cross-react with the immunoassay.6PubMed Central. False-Positive Urine Screening for Benzodiazepines: An Association with Sertraline?
Other substances that have been reported to cause BZO false positives in various immunoassay platforms include efavirenz (an HIV medication) and some herbal supplements, though the evidence for less common triggers varies in strength. The key takeaway is that an initial positive BZO result cannot, on its own, confirm that someone has used a benzodiazepine. Confirmatory testing is needed to determine what substance is actually present.
The False-Negative Problem Is Bigger Than Most People Realize
While false positives get more attention because of their obvious consequences, false negatives on BZO screens are arguably a more widespread issue. Several commonly prescribed benzodiazepines are poorly detected by standard immunoassays. The reason comes down to how different benzodiazepines are metabolized in the body.
Some benzodiazepines, like diazepam, break down through a chain of intermediate metabolites before eventually becoming oxazepam, the target the immunoassay is looking for. Those tend to be picked up reasonably well. But lorazepam, temazepam, and oxazepam itself take a different metabolic route: they are converted almost directly into a glucuronide form, which is a sugar-conjugated molecule that standard immunoassay antibodies do not recognize well.3PubMed Central. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens Lorazepam is particularly prone to false negatives because it is excreted almost entirely as a glucuronide.
This means a person taking lorazepam exactly as prescribed could test negative for BZO on a standard screen. In a pain management or substance abuse monitoring context, that false negative could lead a clinician to incorrectly conclude the patient is not taking their medication, potentially raising questions about diversion. Conversely, in an emergency setting, a negative BZO screen does not reliably rule out benzodiazepine involvement if the patient took lorazepam, clonazepam, or certain other poorly detected drugs.
What Oxazepam Has to Do With Everything
Oxazepam occupies a unique position in benzodiazepine testing because it sits at a metabolic crossroads. It is a prescribed drug in its own right, but it is also the final active metabolite of a long list of other benzodiazepines, including diazepam, chlordiazepoxide, temazepam, halazepam, prazepam, and several others.7PubMed. Metabolic profile of oxazepam and related benzodiazepines: clinical and forensic aspects When a BZO immunoassay comes back positive, and confirmatory testing identifies oxazepam as the metabolite present, it does not necessarily tell you which benzodiazepine the person took. It could be any of the drugs in that metabolic family.
This matters in clinical and forensic settings. If a patient is prescribed diazepam and their confirmatory test shows oxazepam, that is expected and consistent with their prescription. But if someone claims they took only diazepam and the confirmatory test shows a metabolite that is not part of diazepam’s breakdown pathway, that raises different questions. Metabolite profiling, which looks at the ratios between a parent drug and its various metabolites, is an emerging approach that can help distinguish between different patterns of use, including whether exposure was recent or chronic, and sometimes whether the route of administration was unusual.8PubMed Central. Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling
Confirmatory Testing and Why It Matters
When a BZO immunoassay comes back positive (or when a negative result is clinically suspect), the next step is confirmatory testing using a more precise technology, typically liquid chromatography-tandem mass spectrometry (LC-MS/MS). Where the immunoassay casts a wide net, LC-MS/MS identifies specific individual drugs and metabolites by their exact molecular characteristics. A confirmatory panel might test for 19 or more individual benzodiazepines and their metabolites simultaneously.
This distinction between screening and confirmation is critical for understanding what a BZO result actually means. Research comparing immunoassay screening results against LC-MS/MS confirmation has found cases where specimens tested positive on the initial screen but showed no prescribed benzodiazepines at detectable levels on confirmation, representing apparent false positives.9PubMed. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS In some of those cases, the positive screen turned out to be caused by designer benzodiazepines that were not included in the standard confirmation panel, which highlights a newer layer of complexity.
If you receive a positive BZO result on a screening test and have not taken a benzodiazepine, insist on confirmatory testing. Employers, courts, and treatment programs that make decisions based solely on an unconfirmed immunoassay screen are working with incomplete information.
How Long Benzodiazepines Stay Detectable
Detection windows vary enormously depending on which specific benzodiazepine was taken, the dose, how long someone has been using it, and individual metabolic differences. As a rough guide, a single dose of a short-acting benzodiazepine might be detectable in urine for two to five days, while long-acting drugs like diazepam (which has active metabolites with very long half-lives) can be detected for weeks after the last dose in chronic users.
Lorazepam provides a useful case study. After a single 2.5 mg oral dose, urine tested positive for lorazepam for over 144 hours (about six days), with peak urine concentrations occurring around 24 hours after the dose.10PubMed. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes However, that six-day detection window was measured using sensitive LC-MS/MS methods. On a standard immunoassay, lorazepam might not register at all because of the glucuronide issue described earlier, making the practical detection window effectively zero on some screening platforms despite the drug being clearly present in the sample.
Oral fluid (saliva) testing has a much shorter detection window. In the same lorazepam study, oral fluid tested positive for only about eight hours after dosing.10PubMed. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes Hair testing, which is sometimes used for longer detection windows, struggled to detect a single dose of lorazepam at all, unlike most other benzodiazepines that are detectable in hair. The choice of specimen type can substantially affect whether a benzodiazepine is caught.
Designer Benzodiazepines and the Evolving Testing Challenge
A relatively recent complication in BZO testing is the proliferation of designer benzodiazepines, sometimes called novel or illicit benzodiazepines. These are synthetic compounds that are structurally related to traditional benzodiazepines and produce similar effects, but they are not approved as pharmaceutical products. Examples include etizolam, clonazolam, flualprazolam, flubromazolam, and several others.11PubMed Central. Recent findings and advancements in the detection of designer benzodiazepines: a brief review
These substances create a testing headache on both sides. Some designer benzodiazepines cross-react with standard immunoassays, producing positive BZO screens, but they will not show up on standard confirmatory panels that only test for recognized pharmaceutical benzodiazepines. That creates a peculiar situation: the screening test says positive, the confirmation says negative, and the true answer is that the person took something that neither test was fully designed to handle.9PubMed. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS Other designer benzodiazepines may not cross-react with the immunoassay at all, meaning they produce no positive screen despite being pharmacologically active and potentially dangerous.
Laboratories are working to expand their confirmatory panels to include designer benzodiazepines, but it is a moving target. New compounds appear faster than validated analytical methods can be developed for them. If you are a clinician seeing discordant screening and confirmatory results (positive screen, negative confirmation), designer benzodiazepines should be considered as a possible explanation.
When BZO Matters Most for Safety
The clinical significance of a positive BZO result extends beyond the question of whether someone is using benzodiazepines. The bigger concern, from a safety perspective, is often what else the person is taking at the same time. Concurrent use of benzodiazepines and opioids is one of the most dangerous drug combinations. Among Medicare beneficiaries who used both drug classes together, the risk of opioid-related overdose was roughly five times higher during the first 90 days of overlap compared to using opioids alone.12JAMA Network Open. Exposure-Response Association Between Concurrent Opioid and Benzodiazepine Use and Risk of Opioid-Related Overdose in Medicare Part D Beneficiaries Even after the first three months, the elevated risk persisted at roughly double the baseline.
This is why emergency departments routinely run BZO panels on patients presenting with altered consciousness or suspected overdose. It is also why pain management clinics use BZO testing as part of their monitoring protocols. Knowing whether a patient is using benzodiazepines alongside opioids changes clinical decisions about prescribing, dosing, and whether naloxone should be co-prescribed for home use.
The combination is dangerous because both drug classes suppress breathing through different mechanisms. Opioids directly dampen the brain’s respiratory drive, while benzodiazepines enhance GABA signaling that further depresses central nervous system activity.13ACS Chemical Biology. Different Benzodiazepines Bind with Distinct Binding Modes to GABAA Receptors Together, they can suppress breathing to the point of respiratory arrest.
What to Do If You Get a Positive BZO Result
Your response to a BZO-positive test depends on the context. If you have a current prescription for a benzodiazepine, a positive BZO result is expected and should be straightforward to explain. Have documentation of your prescription available, especially if the test was ordered for employment or legal purposes. Keep in mind that some benzodiazepines share metabolites, so confirmatory testing may show oxazepam even if you are taking diazepam or one of its related drugs. That is normal metabolism, not evidence of taking a different drug.
If you are not taking a benzodiazepine and your BZO screen comes back positive, request confirmatory testing. Review your current medications, including over-the-counter drugs and supplements, with the testing provider. Drugs like oxaprozin and sertraline have documented associations with false-positive BZO results, and other medications may contribute as well. Do not accept consequential decisions (job loss, custody changes, treatment modifications) based solely on a screening result without confirmation.
If you are a clinician interpreting results, remember that a negative screen does not rule out benzodiazepine use, particularly for lorazepam, clonazepam, and newer designer compounds. When clinical suspicion is high, order confirmatory testing regardless of the screening result. The immunoassay was designed as a workplace filter, not a comprehensive clinical diagnostic, and treating it as one leads to errors in both directions.
Differences Between Testing Settings
The same BZO abbreviation on a test strip means different things depending on where and why the test was ordered. Workplace drug screens follow federal cutoff standards and typically use a two-step process: immunoassay screening followed by confirmatory testing only for positive results. The emphasis is on minimizing false positives that could unfairly penalize employees.
Emergency department toxicology screens prioritize speed over specificity. Clinicians use them as one piece of information alongside the patient’s symptoms, vital signs, and history. A positive BZO in the emergency room helps guide immediate treatment decisions, even without confirmatory testing, because the clinical situation may not allow time to wait. However, emergency physicians are generally trained to interpret these results cautiously and not rely on them exclusively.
Pain management and addiction treatment programs use BZO testing as part of ongoing monitoring. Here, both false positives and false negatives carry weight. A false positive could lead to unfounded suspicion of illicit drug use, while a false negative could mask a dangerous combination of prescribed opioids and undisclosed benzodiazepines. Some specialized treatment programs have adopted expanded immunoassay panels with improved sensitivity for glucuronidated metabolites, or they skip the screening step entirely and go straight to mass spectrometry-based confirmatory methods.
Forensic and legal testing, such as drug-facilitated assault investigations, requires the most rigorous methodology. Urine remains the preferred specimen for detecting benzodiazepine exposure in these cases, because detection windows in oral fluid are too short and hair testing has significant gaps for certain compounds like lorazepam.10PubMed. Windows of detection of lorazepam in urine, oral fluid and hair, with a special focus on drug-facilitated crimes Even in urine, the analytical method matters: standard immunoassays may miss the exposure entirely, making LC-MS/MS the preferred approach when legal stakes are high.